Zaphyr Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories
2018-003535-30: IFM 2017-03 IFM 2017-03

Not yet recruiting
3
294
Europe
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JnJ-54767414, Solution for injection, Capsule, Pillules, REVLIMID 25 mg gélules, NEOFORDEX 40mg comprimés
CHRU de Lille, CHU de Lille, Janssen Pharmaceutica NV
A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. Etude de phase III comparant le Lénalidomide et le Daratumumab en injection sous cutanée versus le Lénalidomide et la Dexaméthasone chez des sujets fragiles atteints de myélome multiple en traitement de première ligne et non éligibles à une chimiothérapie à forte dose., Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04]
 
 
2021-000292-37:

Not yet recruiting
3
272
Europe
HUMAN NORMAL IMMUNOGLOBULIN (IV), Prednisone, Tablet, , Neofordex 40 mg comprimés
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, DGOS
Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations., Not Done, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-004742-11: A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma

Ongoing
3
560
Europe
Teclistamab, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Imnovid, Dexamethasone, Velcade, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Powder for solution for injection, Darzalex, Imnovid, Neofordex, Velcade
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
FREEDOM, NCT06561854: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Recruiting
3
318
Europe
Dexamethasone, Neofordex
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Relapse Multiple Myeloma
12/28
12/28
IVIORDEX, NCT04968899: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

Recruiting
3
272
Europe
Neofordex®, Dexamethasone, Intravenous immunoglobulins, Tegeline®, Clayrig®,, Gammagard®,, Octagam®,, Privigen®,, Other IgIV patent medicine
Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
04/25
10/26
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Suspended
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/26
01/26
SABLe, NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting
2
50
Europe
Selinexor 20 MG Oral Tablet, Xpovio, Bortezomib Injection, Velcade, Lenalidomide capsule, Revlimid, Dexamethasone Oral, Neofordex
Ida Bruun Kristensen, Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Multiple Myeloma
08/25
06/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories
2018-003535-30: IFM 2017-03 IFM 2017-03

Not yet recruiting
3
294
Europe
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JnJ-54767414, Solution for injection, Capsule, Pillules, REVLIMID 25 mg gélules, NEOFORDEX 40mg comprimés
CHRU de Lille, CHU de Lille, Janssen Pharmaceutica NV
A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. Etude de phase III comparant le Lénalidomide et le Daratumumab en injection sous cutanée versus le Lénalidomide et la Dexaméthasone chez des sujets fragiles atteints de myélome multiple en traitement de première ligne et non éligibles à une chimiothérapie à forte dose., Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04]
 
 
2021-000292-37:

Not yet recruiting
3
272
Europe
HUMAN NORMAL IMMUNOGLOBULIN (IV), Prednisone, Tablet, , Neofordex 40 mg comprimés
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, DGOS
Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations., Not Done, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-004742-11: A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma

Ongoing
3
560
Europe
Teclistamab, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Imnovid, Dexamethasone, Velcade, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Powder for solution for injection, Darzalex, Imnovid, Neofordex, Velcade
Janssen-Cilag International NV, Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
FREEDOM, NCT06561854: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Recruiting
3
318
Europe
Dexamethasone, Neofordex
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Relapse Multiple Myeloma
12/28
12/28
IVIORDEX, NCT04968899: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

Recruiting
3
272
Europe
Neofordex®, Dexamethasone, Intravenous immunoglobulins, Tegeline®, Clayrig®,, Gammagard®,, Octagam®,, Privigen®,, Other IgIV patent medicine
Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
04/25
10/26
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Suspended
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/26
01/26
SABLe, NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting
2
50
Europe
Selinexor 20 MG Oral Tablet, Xpovio, Bortezomib Injection, Velcade, Lenalidomide capsule, Revlimid, Dexamethasone Oral, Neofordex
Ida Bruun Kristensen, Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Multiple Myeloma
08/25
06/29

Download Options